Abstract
Dysglycemia in hospitalized patients, including hyperglycemia, hypoglycemia, and glycemic variability, is associated with adverse clinical outcomes and increased health care utilization. Evidence from landmark trials in critically ill patients supports moderate glycemic targets (140–180 mg/dL) over intensive control. Basal-bolus regimens improve outcomes compared to sliding scale insulin alone in noncritically ill settings. However, limited studies have compared glycemic targets in the noncritically ill hospitalized population. Emerging data support the use of continuous glucose monitoring and diabetes technology in the inpatient setting. Current guidelines emphasize individualized and protocol-driven management to optimize inpatient care.